By letter dated March 21, 2021, Johnson & Johnson (J&J) announced that, effective May 2, 2022, it will no longer honor bill-to/ship-to orders for contract pharmacy arrangements with hospitals unless…
Please see the attached letter to Mr. Charles Clapton, VP of Federal Governmental Affairs with Gilead from RWC-340B President, Shannon Stephenson on behalf of RWC-340B requesting exceptions to MAP/PAP Policies. Should you…
Pfizer and GlaxoSmithKline (“GSK”) are the 13th and 14th manufacturers, respectively, to restrict 340B pricing on drugs shipped to contract pharmacies. Novo Nordisk, which previously restricted access to 340B pricing to one…
President Joe Biden yesterday during a major speech on drug pricing reform applauded U.S. Rep. Abigail Spanberger (D-Va.) for being “relentless in making sure” that the 340B statute “is actually…
Summary The Managing Director of the Ryan White Clinics for 340B Access Coalition (RWC-340B) reports to the Executive Director of United Partners for Human Services (UPHS), the managed service organization…
In response to a rash of reckless decisions by pharmaceutical companies, U.S. Representative Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program and prevent additional…
By email dated January 14, 2022, Bristol Myers Squibb (BMS) announced that, effective March 1, 2022, it will implement a new 340B contract pharmacy policy impacting two drug categories: non-immunomodulatory…
In October 2021, Second Sight, the owner of 340B ESP, updated the Terms of Use (TOU) that covered entities must agree to when registering for the 340B ESP platform. There…
AbbVie is the 11th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies By letter dated December 29, 2021, AbbVie announced that, effective February 1, 2022, it will implement…
By letter dated November 22, 2021, drug manufacturer UCB, Inc. notified covered entities that it is “altering its 340B policy” and will no longer honor contract pharmacy arrangements, effective December…